AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02415517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training on computer. Six sessions with different tasks: Tiere merken \& Räumlich visuelles Training (application BrainTwister) and Taskswitching (programmed with eprime)
Study NCT02415517 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Test of general knowledge
Description: Training of general knowledge on computer. Six sessions with different topics.
Study NCT03942900 — intervention group
Intervention type: OTHER
Intervention: Additional biological samples
Description: * Biomonitoring blood sample will be collected: 6 EDTA tubes (6 mL) for PBMC (peripheral blood mononucleated cell), 1 EDTA tube (6 mL) for plasma freezing and 2 EDTA tubes (4 mL) for ctDNA:~  * at baseline,~ * at first tumor assessment (phase 2 in OPTIMANAL study),~ * at second tumor assessment (phase 4 in OPTIMANAL study),~ * at end-point visit.~* A tumor biopsy or archived tumor sample will be mandatory at baseline.
Study NCT04073251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KalobaTuss children
Description: Syrup, dosage: 5 ml for 4 times a day for 8 days.
Study NCT04073251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Syrup, dosage: 5 ml for 4 times a day for 8 days.
Study NCT03020576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo Hand Robot Device
Description: This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.
Study NCT03020576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
Study NCT01153321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 100mg Oral dose od
Study NCT01153321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD2423 Placebo
Description: Oral dose od
Study NCT03836716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
Study NCT01994759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly
Study NCT01994759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticosteroid injection
Description: Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections).
Study NCT01994759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduction in impact
Description: advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.
Study NCT03527550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Cognitive Control Training involves daily practice with one of two computerized interventions. The first intervention is an adaptive Go/No-Go task to provide practice in the domain of response inhibition. Participants press a key as fast as possible in response to stimuli (letters of the alphabet), but must inhibit responses to a specific letter. The second intervention is an adaptive Paced Auditory Serial Addition Task (PASAT), designed to practice working memory. Participants are presented with single numbers presented aurally, and must add each number they hear to the previous number and click the correct sum on the screen.
Study NCT03502031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin-Angiotensin (RAAS) alone
Description: maximal RAAS blockade alone for 24months.
Study NCT03502031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
Description: maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
Study NCT01767701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg twice daily for 3 months
Study NCT06186661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neurophysiological exercise
Description: The content of the treatment program consisted of neurophysiological exercises based on Bobath.
Study NCT06186661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurophysiological exercise
Description: The content of the treatment program consisted of neurophysiological exercises based on Bobath.
Study NCT06186661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive rehabilitation
Description: Cognitive rehabilitation sessions of the experimental group included 30 minutes of remedial and functional adaptive approaches and 30 minutes of implementation of Multicontextual treatment intervention.
Study NCT01159002 — intervention group
Intervention type: DEVICE
Intervention: SmartPill
Description: Qualifying patients were assigned to the study within four days of hospital admission. They all received a gastro-duodenal tube and capsule. The motility capsule (SmartPill®) was placed into the capsule delivery device (AdvanCE™, US Endoscopy) and advanced blindly into the stomach and released
Study NCT02502903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIV009
Study NCT02502903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIV009
Study NCT02502903 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03177499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive PPG
Description: Invasive PPG obtained by means of catheterization.
Study NCT01844687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CBD
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Study NCT00997893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Soy Placebo
Description: oral placebo pill (0mg Soy Phytoestrogen)
Study NCT00997893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MPA Placebo
Description: oral placebo pill (0mg MPA)
Study NCT01382368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
Study NCT03592810 — intervention group
Intervention type: OTHER
Intervention: Settings of the extracorporeal membrane oxygenation (ECMO)
Description: Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
Study NCT03196154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fasting insulin level
Description: Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
Study NCT00997893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPA Placebo
Description: oral placebo pill (0mg MPA)
Study NCT03327974 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DEPASSE Apllication
Description: Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.~Depasse is available for all on the App store and on Googleplay.~This application has several interests:~- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.~There is the possibility to generate a graph representing the evolution of these parameters.~Tips adapted to the actual mood are provided related to the dysfunctional parameters.
Study NCT03196154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma drug level
Description: Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
Study NCT02373527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Fasting prior to catheterization
Description: No restriction for oral intake
Study NCT02827526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT02827526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT02734927 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: realization of computerized exercises
Study NCT02734927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: realization of computerized exercises
Study NCT02767531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
Study NCT02035124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM 120
Study NCT02035124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study NCT00352183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/Simvastatin
Description: Combination of Fenofibrate and Simvastatin 40mg
Study NCT00352183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40mg
Study NCT00717886 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: isosulfan blue dye
Description: At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies day of mapping for patient convenience.
Study NCT01520753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
Study NCT01520753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administered subcutaneously (s.c., under the skin) at breakfast and lunch
Study NCT01520753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Administered subcutaneously (s.c., under the skin) at dinner
Study NCT03716960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pumpkin Seed Oil
Description: This intervention consisted of 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner).
Study NCT03716960 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention consisted of 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
Study NCT02928484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic mix CBP-004019/C
Description: One capsule per day of the probiotic mix CBP-004019/C during one month.
Study NCT02928484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule per day of the placebo (maltodextrin) during one month.
Study NCT02182804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus
Description: narrow band imaging with magnification
Study NCT02182804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio
Description: probe-based confocal laser endomicroscopy
Study NCT00941551 — intervention group
Intervention type: DRUG
Intervention: levothyroxine
Description: levothyroxine 75-125 ug/day
Study NCT00941551 — intervention group
Intervention type: DRUG
Intervention: no levothyroxine
Description: observation only without prophylactic levothyroxine
Study NCT00797563 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo Blood Glucose Monitoring System
Description: Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
Study NCT04769297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Micro-Dose Ketamine
Description: daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic
Study NCT00025467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT00025467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02826213 — intervention group
Intervention type: DEVICE
Intervention: LifePort® perfusion device
Description: Renal Perfusion with LifePort® perfusion device
Study NCT02826213 — intervention group
Intervention type: DEVICE
Intervention: Waves perfusion device
Description: Renal Perfusion with Waves perfusion device
Study NCT01369550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDA soybean oil-containing foods
Description: 3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.
Study NCT01369550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High-oleic sunflower oil containing foods
Description: 3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day
Study NCT01369550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid
Description: 3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
Study NCT06127732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosterol supplements
Description: Participants were randomized into two groups to receive diet plus phytosterols (DP) for 12 weeks, followed by a 7-day washout period with a second period of intervention, where treatments were switched, and participants received diet alone (D) and were followed for another 12 weeks.
Study NCT01763229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transthoracic echocardiography
Study NCT02424695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil (GEn)
Description: HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:~600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc.
Study NCT02424695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03080285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: over-glasses patch
Description: Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
Study NCT03080285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional patch
Description: Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
Study NCT02768987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright 1 Bodies
Description: A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
Study NCT03638791 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exposure and response inhibition
Description: Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder
Study NCT01578291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental information
Description: An informational brochure indicating the study details
Study NCT01578291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play therapy
Description: Play therapy with a child life specialist
Study NCT03653481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched Inulin OI
Description: Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
Study NCT03653481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
Study NCT04445168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based motivational interviews
Description: 2-year telephone-based motivational interviews to increase physical activity.
Study NCT03583281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules containing flax oil
Description: Capsules containing flax oil to provide 4 grams ALA per day for 4 weeks
Study NCT03583281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules containing DHA-enriched fish oil
Description: Capsules containing fish oil to provide 4 grams DHA per day and 0.8 grams EPA per day for 4 weeks
Study NCT01383278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-directed 5 A's intervention for smoking
Description: Computer-directed 5 A's intervention for smoking
Study NCT01383278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening and resource provision
Description: Screening and resource provision
Study NCT02696798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC
Study NCT02696798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT02696798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00565864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4)
Description: L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
Study NCT04491799 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin
Description: Fecal calprotectin is a protein found in human neutrophils, and it is released during active periods of inflammation of intestine. The sensitivity and specificity has been reported at 93% and 96%, respectively in differentiating inflammatory bowel disease from irritable bowel syndrome in outpatient setting.
Study NCT02926014 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Videolaryngoscopy
Description: A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
Study NCT02926014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Description: A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.